Immunity & good health is determined by the collective presence of living symbiotic, and pathogenic microorganisms in the human microbiome system. Throughout the life cycle age accordingly, bacterial community & its characteristics vary.
Nasal cavity mutualistic bacteria compete for space, and nutrients & produce toxic materials, helping repress pathogenic bacteria and inhibit or kill them. Nasal cavity dysbiosis leads to opportunistic pathogenic bacteria presence, spread in the respiratory tract & the development of allergic rhinitis (AR), chronic rhinosinusitis (CRS), acute respiratory tract infections (ARTI), otitis media (OM), and asthma.
CRS
Instigates disease progression, nasal polyps’ development, chronic symptoms, and sinus cavity inflammatory response. The prevalent presence of Coagulase-negative Staphylococcus, Pseudomonas aeruginosa, and S. aureus influence & modulate the immune response.
Determines asthma onset, advancement, acuteness, metagenomic inference & bacterial glycerolipid metabolism and increase in Prevotella buccalis, Gardnerella vaginalis, P. buccalis, G. vaginalis, Dialister invisus, and Alkanindiges hongkongensis species. Asymptomatic expansion of Streptococcus affects the future possibility, danger & later episodes of asthma and its inflammation symptoms.
In asthma-affected children, Moraxella, Staphylococcus, Corynebacterium, Haemophilus, Fusobacterium, Prevotella, and Dolosigranulum dominate the nasal microbiome environment.
Affects the immune response modulation, pathophysiology & AR growth. In seasonal allergic rhinitis (SAR) patients, pollination season spikes symptoms, nasal eosinophils levels & middle meatus bacterial biodiversity.
Controls host’s susceptibility, influenza-specific immunoglobulin A antibody production disparity, taxa richness rise & the surge of Streptococcus pneumoniae, S. aureus, Phyllobacterium, Moraxella, Staphylococcus, Corynebacterium, and Dolosigranulum in the nasal carriage.
Concomitantly S. pneumoniae transmission increases shooting up protease secretion, activates viral hemagglutinins and modulates the innate immune response. Facilitates influenza, A virus (adenovirus, or rhinovirus) infection & associated respiratory virus infection, S. pneumoniae elevation & invasive pneumococcal pneumonia risk.
Regulates Moraxella, Streptococcus, and Pasteurella spp migration from the middle ear to the nose microbiome & leading to OM. S. pneumoniae, Haemophilus, Actinomyces, Rothia, Neisseria, and Veillonella increase in OM-affected children. OM acute episodes escalate abundant increase of otopathogen genera and decrease in Pseudomonas, Myroides, Yersinia, and Sphingomonas.
The nasal passage is colonized with a diverse range of bacteria, fungi, and viruses and it is the first contact point to the external environment exposure. The nasal microbiota profile positively correlates with amplified immune response. Further research is required to reinforce the promising role of probiotic intervention in the supplementary treatment of nasal dysbiosis-connected respiratory infections.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy
2.
Prostate Cancer Treatment Associated With Long-Term Complications
3.
Unraveling the role of exercise in cancer suppression
4.
Parkinson patient's gait is restored by a spinal cord stimulator.
5.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
1.
The Unseen Danger of Anal Cancer: How to Protect Yourself
2.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
3.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
4.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
5.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation